Search | Clinical Trials Finder

Conditions: Breast Cancer
Interventions: Dato-DXd, Capecitabine, Gemcitabine, Eribulin, Vinorelbine; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 732 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 14
States / cities: Duarte, California • Los Angeles, California • Palo Alto, California + 10 more

Conditions: Breast Cancer, Non-small Lung Cancer
Interventions: Docetaxel, GDC-0032, Paclitaxel; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 10
States / cities: Tampa, Florida • Boston, Massachusetts • Detroit, Michigan + 5 more

Conditions: Breast Cancer
Interventions: Sapanisertib, Fulvestrant, Exemestane; Drug
Lead sponsor: Calithera Biosciences, Inc; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 30
States / cities: Los Angeles, California • San Francisco, California • Santa Barbara, California + 24 more

Conditions: Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Negative, HER2/Neu Negative, Metastatic Malignant Solid Neoplasm, Pancreatic Ductal Adenocarcinoma, Progesterone Receptor Negative, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8, Recurrent Lymphoma, Refractory Lymphoma, Stage II Pancreatic Cancer AJCC v8, Stage IIA Pancreatic Cancer AJCC v8, Stage IIB Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Triple-Negative Breast Carcinoma, Unresectable Solid Neoplasm
Interventions: Oxidative Phosphorylation Inhibitor IACS-010759, Pharmacodynamic Study, Pharmacokinetic Study; Drug · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Hormone Receptor (HR)-Positive Breast Cancer
Interventions: Palbociclib, Everolimus, Exemestane; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Breast Cancer
Interventions: Not listed
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 317 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Advanced/Metastatic NSCLC, Advanced/Metastatic HER2-negative Breast Cancer
Interventions: No drug; Other
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 13,759 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Cambridge, Massachusetts

Conditions: Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer, Metastatic Solid Tumor, Lung Cancer, Ovarian Cancer, Endometrial Cancer, Prostate Cancer, Colorectal Cancer, Breast Cancer, Other Cancer, Locally Advanced, Head and Neck Cancer, Gall Bladder Cancer, Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), Small Cell Lung Carcinoma, NSCLC, NSCLC (Non-small Cell Lung Cancer), SCLC, Non-Small Cell Lung Carcinoma, Triple Negative Breast Cancer, TNBC, HER2+ Breast Cancer, Non-Small Cell Lung Cancer, ER/PR Positive Breast Cancer, HER2- Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, ER/PR(+), Her2(-) Breast Cancer
Interventions: rezatapopt, pembrolizumab; Drug
Lead sponsor: PMV Pharmaceuticals, Inc; Industry
Eligibility: 12 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 32
States / cities: Irvine, California • La Jolla, California • Los Angeles, California + 25 more

Conditions: Adult Solid Tumor, Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Adult Central Nervous System Germ Cell Tumor, Adult Teratoma, Benign Teratoma, Estrogen Receptor-negative Breast Cancer, Estrogen Receptor-positive Breast Cancer, Familial Testicular Germ Cell Tumor, HER2-negative Breast Cancer, HER2-positive Breast Cancer, Male Breast Cancer, Ovarian Immature Teratoma, Ovarian Mature Teratoma, Ovarian Monodermal and Highly Specialized Teratoma, Progesterone Receptor-negative Breast Cancer, Progesterone Receptor-positive Breast Cancer, Recurrent Breast Cancer, Recurrent Colon Cancer, Recurrent Extragonadal Germ Cell Tumor, Recurrent Extragonadal Non-seminomatous Germ Cell Tumor, Recurrent Extragonadal Seminoma, Recurrent Malignant Testicular Germ Cell Tumor, Recurrent Melanoma, Recurrent Ovarian Germ Cell Tumor, Recurrent Rectal Cancer, Stage III Extragonadal Non-seminomatous Germ Cell Tumor, Stage III Extragonadal Seminoma, Stage III Malignant Testicular Germ Cell Tumor, Stage III Ovarian Germ Cell Tumor, Stage IV Breast Cancer, Stage IV Colon Cancer, Stage IV Extragonadal Non-seminomatous Germ Cell Tumor, Stage IV Extragonadal Seminoma, Stage IV Melanoma, Stage IV Ovarian Germ Cell Tumor, Stage IV Rectal Cancer, Testicular Immature Teratoma, Testicular Mature Teratoma
Interventions: PD-0332991; Drug
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 304 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2019
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: HER2-Negative Metastatic Breast Cancer, Recurrent Ovarian Cancer
Interventions: Durvalumab, Eribulin; Drug
Lead sponsor: Amy Tiersten; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Oral Complications, Progesterone Receptor-positive Breast Cancer, Recurrent Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
Interventions: mucoadhesive oral wound rinse, laboratory biomarker analysis; Drug · Other
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Breast Neoplasms
Interventions: PD-0332991, Letrozole, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 666 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2023
U.S. locations: 136
States / cities: Bellflower, California • Beverly Hills, California • Fullerton, California + 83 more

Conditions: Locally Recurrent, Metastatic Breast Cancer ( HER2 Negative)
Interventions: Eribulin mesylate; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 17
States / cities: Miami, Florida • Augusta, Georgia • Macon, Georgia + 13 more

Conditions: Breast Cancer
Interventions: PF-07248144, Fulvestrant, Everolimus, Exemestane; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 102
States / cities: Chandler, Arizona • Gilbert, Arizona • Glendale, Arizona + 85 more

Conditions: Breast Cancer, Metastatic Breast Cancer
Interventions: CT-2103 (Xyotax); Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Advanced/Metastatic Solid Tumors
Interventions: NMS-03305293; Drug
Lead sponsor: Nerviano Medical Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Advanced Solid Tumor, Metastatic Solid Tumor
Interventions: ART6043, Olaparib; Drug
Lead sponsor: Artios Pharma Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 181 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 7
States / cities: Grand Rapids, Michigan • New York, New York • Oklahoma City, Oklahoma + 4 more

Conditions: Breast Cancer, Metastasis
Interventions: Abemaciclib, Bicalutamide; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years to 90 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2028
U.S. locations: 3
States / cities: New York, New York

Conditions: Hormone Receptor Positive Breast Carcinoma, HER2-negative Breast Cancer
Interventions: OP-1250; Drug
Lead sponsor: Olema Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 15
States / cities: Los Angeles, California • Aurora, Colorado • Deerfield Beach, Florida + 11 more

Conditions: Breast Cancer, PALB2-Mutated Breast Carcinoma, HER2-negative Breast Cancer, BRCA1 Mutation, BRCA2 Mutation
Interventions: Axatilimab, Olaparib; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: Breast Neoplasms, Breast Cancer, Cancer of the Breast
Interventions: Lapatinib and Everolimus; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 3
States / cities: Atlanta, Georgia

Conditions: HR+/HER2-negative Breast Cancer
Interventions: TOS-358, Fulvestrant, Palbociclib, Ribociclib; Drug
Lead sponsor: Totus Medicines; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 241 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 9
States / cities: Chicago, Illinois • Boston, Massachusetts • Las Vegas, Nevada + 4 more

Conditions: Breast Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: allogeneic GM-CSF-secreting breast cancer vaccine, recombinant interferon alfa, cyclophosphamide; Biological · Drug
Lead sponsor: Wiseman Research Initiatives LLC; Industry
Eligibility: 18 Years to 120 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 3
States / cities: Glendale, California • Los Angeles, California

Conditions: Advanced Breast Cancer, Metastatic Breast Cancer (HR+/ HER2-), Colorectal Cancer, Metastatic Colorectal Adenocarcinoma, Triple Negative Breast Cancer
Interventions: PF-08032562, Fulvestrant, Cetuximab, Fluorouracil, Oxaliplatin, Leucovorin, Bevacizumab; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 9
States / cities: Duarte, California • Grand Rapids, Michigan • Conroe, Texas + 5 more

Search by objective public record fields.

A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)

A Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer or Non-small Cell Lung Cancer

Safety and Efficacy Study of Sapanisertib in Combination With Exemestane or Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Metastatic Breast Cancer

IACS-010759 in Advanced Cancers

Palbociclib With Everolimus + Exemestane In BC

Treatment Patterns and Clinical Outcomes Among Patients With HR+/HER2- mBC Receiving Palbociclib Combination Therapy in the US Community Oncology Setting.

A Study Assessing Risk Factors for Oral Mucositis/Stomatitis and Ocular Surface Events in NSCLC and Breast Cancer

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer

Durvalumab and Eribulin in Her2-negative Metastatic Breast Cancer and Recurrent Ovarian Cancer

Mucoadhesive Oral Wound Rinse in Preventing and Treating Stomatitis in Patients With ER- or PR-Positive Metastatic or Locally Recurrent Breast Cancer That Cannot be Removed by Surgery Receiving Everolimus

A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2)

A Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

Study of Xyotax (CT-2103) in Patients With Metastatic Breast Cancer

Study of NMS-03305293 in Pts with Selected Advanced/Metastatic Solid Tumors

Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA)

Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer

A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast Cancer

Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast Cancer

A Study of Lapatinib in Combination With Everolimus in Patients With Advanced, Triple Negative Breast Cancer

A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer

Vaccine Therapy in Treating Patients With HER2/Neu Positive or Negative Stage IV Breast Cancer or Other HER2/Neu Positive Cancers

A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors